Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 219.18 CNY -0.43%
Market Cap: 132.2B CNY
Have any thoughts about
Zhangzhou Pientzehuang Pharmaceutical Co Ltd?
Write Note

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Liabilities
ÂĄ299.9m
CAGR 3-Years
-28%
CAGR 5-Years
-13%
CAGR 10-Years
10%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Liabilities
ÂĄ530.5m
CAGR 3-Years
-8%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Liabilities
ÂĄ3.6B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
15%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Other Current Liabilities
ÂĄ506.9m
CAGR 3-Years
59%
CAGR 5-Years
23%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Liabilities
ÂĄ101.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View

Market Cap
132.2B CNY
Industry
Pharmaceuticals

Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.

Intrinsic Value
191.25 CNY
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
299.9m CNY

Based on the financial report for Sep 30, 2024, Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Other Current Liabilities amounts to 299.9m CNY.

What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
10%

Over the last year, the Other Current Liabilities growth was -64%. The average annual Other Current Liabilities growth rates for Zhangzhou Pientzehuang Pharmaceutical Co Ltd have been -28% over the past three years , -13% over the past five years , and 10% over the past ten years .

Back to Top